ABSTRACT Background: Hydrogen sulfide (H 2 S) is a potentially deadly gas that naturally occurs in petroleum and natural gas.
Conclusions: Cobinamide successfully rescued the severely NaHS-poisoned swine from apnea in the absence of assisted ventilation. H ydrogen sulfide (H 2 S) is a potentially deadly gas that occurs in petroleum and natural gas. Newer technologies of extracting oil and gas that are now widely used in the United States, such as hydraulic fracturing, produce excessive concentrations of H 2 S, exceeding the exposure limit set by the U.S. Agency for Toxic Substances and Disease Registry.
1 H 2 S is one of the leading causes of unintentional workplace gas inhalation deaths. 2 Significant exposures (50-400 ppm) may produce difficulty in breathing, agitation, confusion, nausea and vomiting, elevated blood pressure, and loss of consciousness. At higher concentrations H 2 S rapidly causes myocardial infarction, unconsciousness, seizures, acidosis, and death. Just two to three breaths of H 2 S at >700 ppm is immediately fatal. 3 While H 2 S is considered an uncommon cause of poisoning death, deaths due to H 2 S appears to be on the rise. Between 2008 and 2010, the reported instances of intentional death by H 2 S gas inhalation have increased in the United States from two cases to 18 . 4 Furthermore, from 2011 to 2013 states reporting to the Agency for Toxic Substances and Disease Registry's National Toxic Substance Incidents Program reported a total of 43 victims of hydrogen sulfide toxicity including 15 successful suicide victims and 21 victims who were first responders or members of the general public. 5 Research suggests that the incidence of H 2 S suicide is probably underestimated by public health officials. 6 Although the number of suicide reports is relatively small, the mortality rate remains extraordinarily high.
Hydrogen sulfide is also an attractive weapon for terrorists given its high toxicity, difficulty in diagnosing exposure to high concentrations, and the ease with which it can be produced. The New York State Office of Homeland Security specifically identified H 2 S as a possible terrorist chemical weapon because of the ease with which it can be made by combining common household items such as toilet bowl cleaner and dandruff shampoo. 7 Moreover, damage to a hydrogen sulfide-bearing pipeline could disperse a H 2 S cloud causing multiple casualties and pose a significant public safety concern. 8 The toxic effects of H 2 S are due, in part, to inhibition of cytochrome c oxidase, similar to the effects of cyanide toxicity. There are currently several intravenous (IV) antidotes that exist for both poisons, but many antidotes have severe adverse effects, and none have been definitively successful in reversing H 2 S poisoning. In 2006, hydroxocobalamin became available in the United States for treatment of cyanide toxicity, but because of its limited solubility, a large volume of drug is necessary to treat cyanide toxicity and it cannot be administered intramuscularly. Hydroxocobalamin, therefore, is not an ideal drug for first responders. We have evaluated intraosseous and intramuscular administration of cobinamide as an alternative to hydroxocobalamin in an animal model of cyanide toxicity and found cobinamide to be as effective as hydroxocobalamin. 9 However, while there have been some reports of hydroxocobalamin use for hydrogen sulfide, there are no studies evaluating the efficacy of cobinamide for the treatment of severe H 2 S toxicity in a large animal clinically relevant model.
Goal of This Investigation
The primary hypothesis of our study is that IV cobinamide (4 mg/kg in 0.8 mL of 225 mmol/L solution) is more effective than either IV hydroxocobalamin (4 mg/kg in 5 mL of saline) or saline alone in reversing the effects of potentially survivable H 2 S toxicity; that is, cobinamide will prolong survival. The model we developed produces apnea, significant hypotension, and biomarkers that closely parallel exposure of >500 ppm.
2,10 Specifically, we compared survival time and evaluated time to spontaneous ventilation, defined as six consecutive breaths, among groups of swine with acute H 2 S-induced apnea treated with IV cobinamide (tetranitrocobinamide, 225 mmol/L solution), IV hydroxocobalamin, or saline.
METHODS

Materials
Sodium hydrogen sulfide (NaSH) and hydroxocobalamin were purchased from Sigma Aldrich and Meridian Medical Technologies, respectively. Cobinamide was generated from hydroxocobalamin by base hydrolysis using cerium hydroxide; it was >96% pure as determined by high-performance liquid chromatography.
Study Design and Setting
We conducted a randomized comparative laboratory investigation. The study was approved by our Institutional Animal Care and Use Committee at the Wilford Hall Ambulatory Surgical Center Clinical Research Division. All procedures involving animals complied with the regulations and guidelines of the Animal Welfare Act, the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the American Association for Accreditation of Laboratory Animal Care. The housing of animals and the performance of the study took place in the Animal Care Facility at our institution. Our study was funded by the U.S. Air Force Office of the Surgeon General and by the NIH CounterACT Program, Office of the Director, NINDS, Grant NS87964.
Animal Subjects
Female Yorkshire swine (Sus scrofa; N = 24, weighing 45-55 kg) were medicated with intramuscular ketamine 10 mg/kg. General anesthesia was induced with isoflurane via nose cone. Following endotracheal intubation, the animals were mechanically ventilated with a volume-limited, time-cycled ventilator (Fabius GS anesthesia machine, Drager-Siemens) and maintained with inhaled isoflurane (1%-2.5%) and oxygen (FiO 2 of 0.4-0.45). The tidal volume was initially 10 mL/kg and respiratory rate was 10 breaths/min. The minute ventilation was adjusted to maintain an end-tidal CO 2 value between 38 and 42 mm Hg as measured by inline capnography. Lead II of the surface electrocardiogram was monitored continuously. Temperature was maintained at 37.5-39.0°C.
Animal Preparation
Invasive hemodynamic variables were measured with an eight-French Swan-Ganz CCOmbo V pulmonary artery catheter (Model 777F8) and the Edwards Vigilance II monitor (Edwards Lifesciences, Irvine, CA). Measurements included continuous cardiac output (CO), systemic vascular resistance, mixed venous oxygen saturation (SVO 2 ), mean arterial pressure (MAP), heart rate (HR), and core temperature. The catheter ports were flushed with saline and the catheter was placed via cutdown in the right external jugular. Arterial pressure was measured continuously through the femoral artery. An 8.5-French introducer (Arrow) was placed in the carotid artery for laboratory sampling and another was placed in the internal jugular for medication administration. The animals received a warmed saline IV bolus (20 mL/kg) during procedure setup. The Fabius GS anesthesia data collection software embedded in the ventilator's computer was used for data acquisition at 1-minute intervals.
Baseline biochemical measurements included oxygen saturation, PaO 2 Following instrumentation, isoflurane was reduced to 0.5%-1.5% after which animals were acclimated and stabilized for 10 minutes. After stabilization, anesthesia was adjusted such that animals would spontaneous ventilate with an FiO 2 of 0.21, without mechanical ventilator assistance. Successful weaning from ventilator, defined as spontaneous ventilation with minute volume of ≥7.0 L/min, EtCO 2 50-53 mm Hg, oxygen saturation ≥ 95%, and respiratory rate 25-35 breaths/min was confirmed prior to the start of the sodium hydrosulfide (NaHS) infusion.
Sodium hydrosulfide (Sigma Aldrich), dissolved in sterile saline at a concentration of 8 mg/mL, was prepared minutes before each experiment. The infusion rate was determined previously on the basis of pilot experiments not included in the data presented here. The solution was infused using an infusion pump (Plum A+ infusion system, Hospira) at 1 mg/ kg/min and continued at that rate until apnea occurred, confirmed for 20 seconds by capnography. The NaHS infusion rate was sustained for 1.5 minutes postapnea, decreased to 0.7 mg/kg/min for 3 minutes, and then decreased again to 0.1 mg/kg/ min for the remainder of the study. Animals were randomly assigned, using a random-number generator (https://www.randomizer.org) to receive saline, cobinamide (4 mg/kg), or hydroxocobalamin (4 mg/ kg) 1 minute postapnea, and then monitored for 60 minutes.
Methods of Measurement and Outcome Measures
Because this model was, as intended, a lethal but potentially survivable model of H 2 S toxicity, survival time and time to spontaneous ventilation were primary outcomes. We also compared CO, MAP, systemic vascular resistance, SvO 2 , and HR. Hemodynamic measurements were recorded at 1-minute intervals and analyzed at 1-minute intervals from the start of the NaHS infusion until approximately 10 minutes postapnea. Serum blood sampling for arterial blood gases was taken at baseline; 5 minutes after NaHS infusion start (unless apnea occurred prior to the 5-minute mark); 5 minutes postapnea; and for survivors 10, 20, 40, 50, and 60 minutes after treatment. Urine sampling for urine TS was drawn at baseline; 5 minutes after NaHS infusion start; 1, 2, 4, 6, 8, and 10 minutes postapnea; and for survivors 20, 30, 40, 50, and 60 minutes postapnea. Cytokine sampling was taken at baseline; 5 minutes after NaHS infusion start (unless apnea occurred prior to the 5 minute mark); at apnea; and for survivors 20, 30, 40, 50, and 60 minutes postapnea.
Quantitation of Serum Cytokine Concentrations
Serum was collected with the appropriate vacutainer blood collection tube and frozen at -80°C. After completion of the experiment, cytokines were analyzed in duplicate via enzyme-linked immunosorbent assay (ELISA) according to manufacturer's instructions. Tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6, and IL-10 were analyzed using pig-specific kits (R&D Systems). ELISA plates were analyzed using BIO-TEK Synergy H4 microplate reader with Gen5 software.
HPLC Analysis
We measured urine TS concentrations to confirm that all animals were exposed to NaHS. Elevated urine TS concentrations have been used to demonstrate HS exposure incidents in the workplace. 12 TS was determined by a modified and validated HPLC method as described. 13, 14 To prevent premature HPLC column plugging by particulates, centrifugation as well as precolumn guards were utilized.
Eighty-five microliters of urine was aliquoted to a polypropylene microcentrifuge tube and derivatized with 102 lL of 7.66 monobromobimane in acetonitrile, followed by 85 lL of 160 mmol/L-16 mmol/L in water of HEPES-EDTA at pH 8.0 with vigorous mixing. The reaction was stopped after 30 minutes in the dark by 170 lL of 65 mmol/L methanesulfonic acid. Particulates were removed by centrifugation, and the supernatant was transferred to autosampler vials for HPLC fluorescence analysis.
High-performance liquid chromatography was performed using a Waters-2695 module, coupled to a 474 (Waters) fluorescence detector (excitation 380 nm, emission 480 nm) and a Waters Symmetry C18 Cartridge, 100 A, 5 lm, 4.6 9 250 mm (WAT054215) reverse-phase column. PIPES (10 mmol/L, pH 6.6) and methanol (isocratic 50:50) were used at a flow rate of 0.75 mL/min. Area under the curve of the TS peaks was integrated by the software of the Waters-2695 device.
Linearity was obtained from 10 to 400 lmol/L TS and a maximal intraday and interday variability of 7.3 and 10.0%, respectively. The lower level of detection was approximately 5.0 lmol/L.
Urinary creatinine concentrations were measured using a Sirrus chemistry analyzer. TS concentrations were normalized to these concentrations for expression of lg sodium TS (STS) per mg urine creatinine (uCr).
Data Analysis
Power Analysis. Power was assessed using G*Power Version 3.1. Return to spontaneous ventilations among groups in our cyanide studies 9 was used to estimate a priori power as it is a critical measure of outcome. G power analysis using the Z-test, difference between two independent proportions, determined that equal group sizes of 14 animals were needed to achieve a power of 80% in detecting a 50% difference in the primary outcome of return to spontaneous ventilations at a significance level of a = 0.05. However, data collection terminated after data were collected on eight animals per group as it was clear that only the cobinamide-treated animals survived.
Descriptive Statistics. Means, standard deviations (SDs), and standard errors of measurement were calculated for variables of interest. Frequency distributions were calculated for discrete variables of interest. Descriptive statistics were analyzed using multivariate analysis of variance (MANOVA).
Primary Outcome Parameters. Mean values for time to spontaneous ventilation after apnea were compared among groups using repeated-measures analysis of variance. Survival time was analyzed by developing Kaplan-Meier curves for each treatment and the survival distributions compared using a three-sample log-rank test using Kaplan-Meier analysis. A priori death was defined as a MAP less than 20 mm Hg for 10 minutes.
Secondary Outcome Parameters. Secondary outcome variables were modeled using repeated-measures multivariate analysis of variance (RMANOVA) with adjustment for treatment, time, and the interaction of treatment by time with an autoregressive covariance structure assumed. Post hoc analysis was performed on all variables that showed a significant treatment by time interaction, for which treatment contrasts were measured at each post treatment time point with a Bonferroni adjustment for multiple testing applied.
All statistical testing was two sided with a significant level of alpha of 0.05 and completed using SAS Version 9.3 and IBM SPSS Statistics Version 22. All graphical presentations were made using R Version 2.15.1. Mean values for the following variables were compared among groups using RMANOVA: MAP, HR, CO, and SVO 2 . Because of the different sampling times, PaO 2 , PCO 2 , SaO 2 , oxyhemoglobin percent, pH, and serum lactate values were analyzed with a second RMANOVA. Urine TS and inflammatory markers-TNF-a, IL-1b, IL-6, and IL-10 were analyzed separately using RMANOVA. Data met the assumptions for RMANOVA and ANOVA such as the following assumptions: 1) random samples, 2) normal distribution, and 3) group sizes equal. No group comparisons were analyzed after NaHS had been infused for 10 minutes as time points after 10 minutes did not contain sufficient data; i.e., animals in the hydroxocobalamin and control groups were not surviving.
Post Hoc Tests. In the event of significant multivariate effects, multiple univariate RMANOVA and contrasts were used to investigate effects for vital signs and biomarkers using the Hochberg or BonferroniHolm procedure to correct the level of significance for multiple comparisons.
RESULTS
Characteristics of Study Subjects
At baseline, the groups had similar vital signs and biochemical variables (MANOVA p > 0.05; Table 1 ). Results are reported as mean AE SD. There were no significant differences in mean end-tidal isoflurane percent by group during the period of spontaneous ventilation (mean AE SD isoflurane cobinamide, 1.18 AE 0.2; hydroxocobalamin, 1.07 AE 0.07; control 1.05 AE 0.2; p > 0.3). There were no significant differences in the total dose (p = 0.3) or the mg/kg dose (p = 0.45) of NaHS to produce apnea among the groups, nor was there a difference in the time required for NaHS to produce apnea (p = 0.42; Table 2 ). Although urine TS concentrations increased over time for all groups (within-group difference; p < 0.05), suggesting that NaHS was producing toxicity, there were no between group differences over time from start of infusion to 8 minutes postapnea (Table 3) . Concentrations of urine TS are expressed as lg STS/mg uCr. Low concentrations of TS can be expected in baseline urine due to metabolism of dietary proteins as well as Data presented as mean (AESD). There were no significant differences. CO = cardiac output; COB = cobinamide; HOC = hydroxocobalamin; HR = heart rate; MAP = mean arterial pressure; STS = sodium thiosulfate.
other compounds containing sulfur groups as a result of enzyme pathways involving sulfur metabolism; 15 therefore, baseline urine TS concentrations may have high variability. The large variability of TS concentrations at each time point likely contributed to our not finding any significant differences between the groups at any time.
Primary Outcome
Whereas all of the cobinamide-treated animals survived through the 60-minute observation period, none of the control or hydroxocobalamin-treated animals survived past 15.4 AE 2.3 minutes. None of the control or hydroxocobalamin-treated animals met our definition of return to spontaneous ventilation, defined as six consecutive breaths. Therefore, time to spontaneous ventilations was not compared among the groups. The mean time to spontaneous ventilations for the cobinamide group was 3.23 AE 1.1 minutes. Survival was calculated from the start of the study to death, defined as a MAP below 20 mm Hg for 10 minutes. Kaplan-Meier method of survival analysis clearly showed a significant difference by group (log rank p < 0.001; Figure 1) . Mean survival times for the control group were 15.4 AE 2.3 and 14.9 AE 2.4 minutes for the hydroxocobalamin-treated group.
Secondary Outcomes
There were no significant differences in vital signs (Table 4) or arterial blood gas values (Table 5 ) among the groups from baseline to 1 minute postapnea, which was designated treatment time, with the exception of the cobinamide group, which demonstrated a lower oxygen partial pressure at 1 minute postapnea compared to the other groups (p < 0.05). At 10 Data presented as mean (AESD). There were no significant differences. COB = cobinamide; HOC = hydroxocobalamin; NaHS = sodium hydrosulfide. Data presented as mean (AESD). There were no significant differences between the groups. There was a significant within-group difference such that by 2 minutes postinfusion all groups had significantly higher levels of urine TS compared to baseline (p < 0.05). COB = cobinamide; HOC = hydroxocobalamin; STS = sodium thiosulfate. *Significant difference. Figure 1 . Survival analysis using a Kaplan-Meier course plot estimate comparing all the groups of NaHS-infused animals. IV-COB = intravenous cobinamide; IV-HOC = intravenous hydroxocobalamin.
ORIGINAL CONTRIBUTION • September 2017, Vol. 24, No. 9 • www.aemj.org minutes postapnea, whereas the cobinamide animals were recovering, hydroxocobalamin-treated and control animals continued to deteriorate which was reflected in vital signs and arterial blood gas values (RMA-NOVA p < 0.01). Vital signs are graphically depicted in Figure 2 . Aggregate data analysis of proinflammatory cytokines IL-1b, TNF-a, and IL-6 demonstrated an increase in all groups from baseline to apnea (p < 0.05; Figure 3 [data shown in aggregate. Data after 10 minutes reflect cobinamide group only]). When proinflammatory cytokines were compared by group, the control group had significantly greater increase in TNF-a (Figure 4 ) compared to the IV cobinamide group (p < 0.03). No other pairwise comparisons were significant. Values for IL-10 did not significantly change over the observation period. There were no significant differences in coagulation biomarkers.
DISCUSSION
Intravenous cobinamide (4.2 mg/kg; 0.8 mL) successfully resuscitated all NaHS toxic animals, whereas neither hydroxocobalamin (4 mg/kg; 5 mL) nor control (saline) provided effective resuscitation. Indeed the mean time to spontaneous ventilation, six consecutive breaths, after treatment with cobinamide was 3.23 minutes with no animal in that group taking longer than 5.3 minutes (range = 1.5-5.3 minutes) to spontaneously ventilate. No animal in either of the other two groups had sufficient respiratory effort posttreatment to reach our definition of return to spontaneous ventilation. Treating animals at a time when they were apneic would likely be similar to clinical scenarios, since apnea occurs quickly after H 2 S exposure, and lowering the NaSH infusion rate postapnea would also likely be similar to a clinical scenario of removing a person from the sulfide-contaminated area. Vital signs Data presented as mean (AESD). CO = cardiac output; COB = cobinamide; HOC = hydroxocobalamin; HR = heart rate; MAP = mean arterial pressure; SvO 2 = mixed venous oxygen saturation. *Significant differences.
and arterial blood gases continued to deteriorate in the hydroxocobalamin and control groups posttreatment, but improved in the cobinamide-treated group, supporting the premise that cobinamide successfully resuscitates swine with apnea induced NaHS toxicity. Urine STS levels demonstrate the initial significant (p < 0.05) increase in the biological marker for toxicity 16 with subsequent decrease in those animals that survived (Table 3) .
Cytokine data support the model as a toxic but survivable model. Similar to cyanide-induced cytokine upregulation, 17 a NaHS infusion induced TNF-a, IL1b, and IL-6. Expression of TNF-a increased within minutes following the NaHS infusion and in the case of the cobinamide-treated animals began to decrease after treatement. 18 IL-1b and IL-6 also increased, but had more sustained increases in expression such that there were no difference among the groups. Because most of the animals in the hydroxocobalamin and control groups did not survive past approximately 10 minutes, finding an increase in the expression of IL-10 would be unlikely. Interestingly, the expression of TNF-a decreased after treatment with hydroxocobalamin as well as cobinamide, suggesting that hydroxocobalamin may have provided some benefit (although time of survival did not change). It is not clear if the cytokines were induced due to apnea/hypoxia or some other mechanism. Hypoxia is known to affect cytokine production such that IL-b, IL-6, IL-8, and TNF-a are upregulated. 19 However, physiologic concentrations of NaHS have been shown to attenuate secretion of proinflammatory cytokines. 20, 21 Whether the effect of NaHS on cytokine production is a dose-dependent function is unclear.
Serum concentrations of sulfide decreased after administration of hydroxocobalamin for H 2 S toxicity, suggesting that hydroxocobalamin may be efficacious in other doses. 22 Our intent in this experiment was to demonstrate that cobinamide is more efficacious compared to hydroxocobalamin on a mg/mg basis. We have previously shown that hydroxocobalamin is as effective as cobinamide in reversing cyanide toxicity but five times more hydroxocobalamin than cobinamide was required. Acute H 2 S toxicity (>500 ppm) causes central neurotoxicity, apnea, and pulmonary edema. 23 Because our model is not an inhalation model, alveolar injury with subsequent pulmonary edema was not evident. However, central nervous system effects were apparent. It has been suggested that the central nervous system effects of H 2 S are due to inhibition of cytochrome c oxidase, similar to cyanide toxicity. Inhibition of cytochrome c oxidase and thus inhibition of oxidative phosphorylation causes decrease adenosine triphosphate production, a shift to anaerobic metabolism, and subsequent metabolic acidosis. 24 Although we cannot directly attribute the metabolic acidosis seen in our animals to inhibition of cytochrome c oxidase, it likely contributed to lactic acidosis together with apnea.
Because all animals had equivalent treatment until 1 minute after apnea, we analyzed grouped data from baseline to apnea to further evaluate our model. We found that SVO 2 , SaO 2 , oxyhemoglobin, peripheral oxygen saturation, MAP, and CO decreased over that time, with the most significant decrease occurring at apnea (Tables 4 and 5 ). If NaHS inhibits cytochrome c oxidase in a manner similar to H 2 S or cyanide poisoning, it might be expected that neither SaO 2 nor oxyhemoglobin would decrease. However, it has been postulated that poisoning from H 2 S produces a significant decrease in CO and cardiac contractility from blockade of L-calcium channels in cardiomyocytes and that the effects of this blockade happen more rapidly than the effects of inhibition of cytochrome c oxidase. 24 Because time from the start of the NaHS infusion to the apneic event was short (5.28 AE 4.2 min) and because we did not measure molecular events, it is difficult to say with certainty which factors contributed to the decreases in oxygenation and CO. What is clear is that cobinamide was 100% successful in rescuing the NaHS toxic animals whereas hydroxocobalamin or no treatment did not.
Cobinamide, a water-soluble cobalamin analog, has a high binding affinity for cyanide and sulfide. Because, the major toxic effect of H 2 S is similar to cyanide, i.e., inhibition of cytochrome c oxidase, we speculated that cobinamide would reverse the effects of H 2 S toxicity. Administration of cobinamide produced a return to normal respirations and oxygenation, an increase in HR above baseline, a moderate increase in MAP, and an increase in CO. These trends are congruent with our experiments examining the efficacy of cobinamide to treat cyanide toxicity. 9 Although hydroxocobalamin has been shown to bind sulfide and TS, 22 it was not clinically effective in this model at the same mg/kg dose as cobinamide. This result is consistent with our previous work with cyanide where the effective hydroxocobalamin dose was about five times greater than the cobinamide dose required to treat severe cyanide poisoning in a swine model. 9 Cobinamide's greater potency against cyanide and sulfide compared to hydroxocobalamin is because cobinamide: 1) has a greater affinity for the CN -and HS -ions, 2) has a higher rate of complex formation with these ions, and 3) can neutralize two CN -and HS -ions per mole instead of only one. 25, 26 The volume of hydroxocobalamin necessary to deliver 4 mg/kg was three times greater than that of cobinamide, because hydroxocobalamin is less water soluble. Hence hydroxocobalamin cannot be administered intramuscularly, making it less attractive as an antidote for mass casualty situations.
LIMITATIONS
There were a number of limitations to this study. First, we infused NaHS rather than use a H 2 S inhalation model. The IV infusion model allowed us to tightly control the level of toxicity and prevented exposure of laboratory personnel to potential leaks of H 2 S gas. However, given that the swine developed symptoms and findings similar to those described in patients who inhale H 2 S and given that H 2 S is primarily a mitochondrial inhibitor, the route of exposure may not be essential. Other models have used IV infusion to validate antidotes. Nevertheless, the results may have been different had we used an inhalation model where inhaled hydrogen sulfide has different kinetics. Second, we used an equal dose of hydroxocobalamin and cobinamide. A larger dose of hydroxocobalamin may have proved efficacious. However, our intent in this study was to compare equal doses of hydroxocobalamin and cobinamide for the treatment of H 2 S poisoning. Finally, the study was not blinded; however, we have meticulously reported the objective criteria, i.e., time to death, vital signs, and urine TS concentration, to limit subjective interpretations.
CONCLUSION
We have shown that cobinamide was 100% effective in this fatal model of NaHS toxicity, and that ORIGINAL CONTRIBUTION • September 2017, Vol. 24, No. 9 • www.aemj.org cobinamide was significantly more efficacious than hydroxocobalamin when compared at equal mg/kg dosages. Moreover, this model appears to be robust and potentially may be used to evaluate other antidotes to H 2 S. Further research is necessary to determine if cobinamide may serve as an effective antidote, particularly in areas with a high risk of exposure such as fracking areas.
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